• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 8, Issue 3
  3. Author

Online ISSN: 2515-8260

Volume8, Issue3

Assessment of CD96 expressionin Acute Myeloid Leukemia Patients

    Eman A. EL Moqammar, Mustafa N.M, Hany A Labib , Ahmed A Alnagar, Mohamed Eissa

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 3, Pages 3686-3697

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Background:Acute myeloid leukemia (AML) is a clonal malignant disease of hematopoietic
tissues that is defined by the accumulation of leukemic blast cells in the marrow resulting in
hematopoietic failure.Among human peripheral blood cells,Cluster of Differentiation 96
(CD96) expression was observed on T and Natural Killer (NK) cells but not on the majority of B
cells, monocytes, and granulocytes. In contrast to the role of CD96 participating in immune
surveillance of tumors, CD96 itself was identified as a tumor marker. Indeed, well before first
studies deciphered its functions, CD96 was reported to be upregulated in subpopulations of TAcute
lymphoblastic leukemia (ALL) and AML. Increased expression of CD96 was shown in
several subsequent studies to correlate with poor prognosis and enhanced resistance to
chemotherapy. A promising treatment strategywould therefore be to sort out CD96-expressing
stem cells before autologous transplantation of AML patients.
Keywords:
    Acute myeloid leukemia (AML).Cluster of Differentiation 96 (CD96)
  • PDF (400 K)
  • XML
(2021). Assessment of CD96 expressionin Acute Myeloid Leukemia Patients. European Journal of Molecular & Clinical Medicine, 8(3), 3686-3697.
Eman A. EL Moqammar, Mustafa N.M, Hany A Labib , Ahmed A Alnagar, Mohamed Eissa. "Assessment of CD96 expressionin Acute Myeloid Leukemia Patients". European Journal of Molecular & Clinical Medicine, 8, 3, 2021, 3686-3697.
(2021). 'Assessment of CD96 expressionin Acute Myeloid Leukemia Patients', European Journal of Molecular & Clinical Medicine, 8(3), pp. 3686-3697.
Assessment of CD96 expressionin Acute Myeloid Leukemia Patients. European Journal of Molecular & Clinical Medicine, 2021; 8(3): 3686-3697.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 109
  • PDF Download: 336
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus